Loading stock data…
HRTX
$1.22-0.05 (-3.94%)
Pre-Market$1.22+0.00 (+0.06%)· Last close May 4
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Heron Therapeutics, Inc. in the Healthcare sector is trading at $1.22. The stock is currently 53% below its 52-week high of $2.61, remaining 1.6% below its 200-day moving average. Technical signals show overbought RSI of 75 and bullish MACD crossover, explaining why HRTX maintains its current current market pressure. The Whystock Score of 0/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 75) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.22
Potential Upside
5%
Whystock Fair Value$1.28
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, w...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$192.31M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-6.50%
Volume
Today's trading volume
2.12M
Recent News
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Heron Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Heron Therapeutics, Inc.'s Q4 2025 earnings call
Heron Therapeutics Inc (HRTX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...
Heron Therapeutics Inc (HRTX) surpasses revenue expectations while navigating oncology declines and regulatory hurdles.